Corcept Therapeutics (CORT) Stock Forecast & Price Target
Score
Corcept Therapeutics Incorporated price target
| CORT | |
|---|---|
| Low | $50.00 |
| Average | $132.80 |
| High | $165.00 |
| Upside vs current price | +82.1% |
The average target of $132.80 is +82.1% versus the current CORT price of $72.94.
Corcept Therapeutics Incorporated analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 3 |
| Hold | 0 |
| Sell | 1 |
| Strong sell | 0 |
| Consensus | Buy |
5 analysts cover CORT.
Corcept Therapeutics Incorporated EPS and revenue estimates
CORT shows the next fiscal years with at least three analysts: 2026 EPS $2.07, 2027 EPS $4.17. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $2.07 | $1.15B |
| 2027 | $4.17 | $1.68B |
Is Corcept Therapeutics Incorporated a buy or sell?
Of the 5 analysts covering Corcept Therapeutics Incorporated, 4 rate it a buy (1 strong buy and 3 buy), 0 rate it a hold, and 1 rates it a sell (1 sell and 0 strong sell).
The CORT consensus label is Buy, beside 4 buy-side ratings and 1 sell-side ratings.
The average target of $132.80 implies +82.1% versus the current price of $72.94.
Those 5 ratings on CORT are a headcount, and the label on file is Buy.
Reading the Corcept Therapeutics Incorporated forecast
The CORT target range is wide: $50.00 at the low end, $132.80 in the middle, and $165.00 at the top.
Set next to the $72.94 CORT quote, that average is +82.1%.
Ratings on the Corcept Therapeutics Incorporated cluster: 4 of 5 analysts are on the buy side, 0 are at hold, and 1 is on the sell side, and the published consensus is Buy.
Recent CORT revisions are two-sided: 0 upgrades and 1 downgrades.
The CORT EPS path from 2026 ($2.07) to 2027 ($4.17) is rising.
Only 5 analysts cover CORT, so the average rests on a short list.
Corcept Therapeutics Incorporated forecast questions
What is the CORT price target?
The published range for CORT is $50.00 to $165.00, with an average of $132.80. That average is +82.1% versus the current price of $72.94.
Is Corcept Therapeutics Incorporated a buy or sell?
Of the 5 analysts covering Corcept Therapeutics Incorporated, 4 rate it a buy, 0 rate it a hold, and 1 rates it a sell. The consensus is Buy, and the CORT headcount is 4 buy, 0 hold, and 1 sell.
What is the EPS estimate for Corcept Therapeutics Incorporated?
Analyst EPS estimates for Corcept Therapeutics Incorporated: 2026 $2.07, 2027 $4.17.
What is the revenue estimate for Corcept Therapeutics Incorporated?
Analyst revenue estimates for Corcept Therapeutics Incorporated: 2026 $1.15B, 2027 $1.68B.
How many analysts cover CORT?
5 analysts cover CORT. Their consensus on CORT is Buy, across those 5.